Zerodha (Trading Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Zerodha (Trading Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
|
Dilip Davda, Indsec Securities and Swastika Investmart Ltd have given "Apply" recommendation to Akums Drugs and Pharmaceuticals IPO. Capital Market has given "May Apply" recommendation to Akums Drugs and Pharmaceuticals IPO.
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 3 | 1 | 0 | 0 | 0 |
| % | 75.00 | 25.00 | 0.00 | 0.00 | 0.00 |
| Reviewer | Recommendation | Past Reviews |
|---|---|---|
Capital Market |
May Apply |  |
| Dilip Davda | Apply | |
| Indsec Securities |
Apply | |
| Swastika Investmart Ltd |
Apply | |
The Captial Market (CapitalMarket.com) rating for Akums Drugs and Pharmaceuticals IPO is 45. Their analysis recommends May subscribe for the IPO.
| Reviewer | Rating Score | Rating |
|---|---|---|
| Capital Market | 45 | May subscribe |
[Dilip Davda] The company is enjoying a leadership in CDMO segment and has many blue-chip domestic as well as global pharma companies as its loyal customers. If we consider the restated performance excluding put call liabilities, the IPO is priced at a P/E of 29.79 based on FY24 earnings. The issue appears fully priced. Investors may park funds for the medium to long term. Read detail review...
Akums Drugs and Pharmaceuticals Limited peer comparison with similar listed entities. (As on March 30, 2024)
| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Akums Drugs and Pharmaceuticals Limited | -0.28 | -0.28 | 49.59 | -0.57 | 13.69 | ||
| Divi's Laboratories | 60.27 | 60.27 | 511.21 | 74.99 | 11.79 | 7.24 | |
| Suven Pharmaceuticals Limited | 11.80 | 11.80 | 80.56 | 69.54 | 14.64 | 10.19 | |
| Gland Pharma Limited | 46.90 | 46.89 | 483.41 | 42.45 | 8.85 | 4.12 | |
| Torrent Pharmaceuticals Ltd. | 48.94 | 48.94 | 202.57 | 60.20 | 24.15 | 14.54 | |
| Alkem Laboratories Ltd | 150.19 | 150.19 | 862.46 | 34.18 | 17.41 | 5.95 | |
| Eris Lifesciences Ltd | 28.82 | 28.79 | 190.12 | 34.95 | 15.16 | 5.29 | |
| JB Chemicals | 35.66 | 34.85 | 188.37 | 51.38 | 18.90 | 9.51 | |
| Mankind Pharma Limited | 47.75 | 47.68 | 233.73 | 44.65 | 20.43 | 8.80 | |
| Innova Captab Limited | 18.66 | 18.66 | 145.20 | 29.91 | 11.35 | 3.84 |
Source:
Akums Drugs and Pharmaceuticals IPO Reviews, analysis and views by popular members. Read Akums Drugs and Pharmaceuticals Limited IPO reviews by retail investors to find recommended ipo to buy.
Post Recommendation Manage Your IPO Reviews
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 6 | 4 | 0 | 1 |
| % | 54.55 | 36.36 | 0.00 | 9.09 |
| Member | Review |
|---|---|
| Mirshad Kanyana |
Apply for Listing Gain at Cut-off Price 2 days subscription showing the chance of listing gain July 31, 2024 4:15:48 PM |
| Alpesh Jain A |
Apply for Listing Gain at Upper Price Band Apply July 31, 2024 2:47:06 PM |
| Pradeep Bishnoi |
Apply for Listing Gain at Cut-off Price I'm not promoting this IPO. This is my view on it. I strongly believe that this IPO will get 25 to 35% listing gain. This is a B to B company so profit will not be jump dramatically so don't recommend to hold for long time.
|
| BABUKALIA |
May Apply for Long Term at Upper Price Band APPLY July 30, 2024 4:11:01 PM |
| Mayank Gupta |
May Apply for Long Term at Cut-off Price The majority of debt and the put-call liabilities would go away post-listing. Hence, ratios should improve and long-term investors can look to hold. July 30, 2024 3:44:11 PM |
| Prabhatranjan |
Apply for Listing Gain at Upper Price Band This very good company July 30, 2024 12:46:07 PM |
| B SURYA PRAKASA RAO |
Avoid Loss during 2022 and steep decline in NP between 2023 and 2024. ROE, RONW is very low. And very steeply priced for a share with FV of ₹2. July 30, 2024 8:32:32 AM |
| Ankit Dhakad |
May Apply for Short Term at Cut-off Price Only risk-taking investors should apply. The company's clients include many big names. However, the company is not financially strong.
|
| N Goyal |
Apply for Long Term at Upper Price Band leader in the segment , good repute July 28, 2024 9:29:25 PM |
| Caarlos |
Apply for Listing Gain at Cut-off Price Apply for listing gain July 27, 2024 2:06:29 PM |
| Dhanvantri |
May Apply for Listing Gain at Upper Price Band Loss Making Company May Apply for listing gains .Retail 10% Due to lossaking. July 27, 2024 6:25:33 AM |
Post Recommendation Manage Recommendations
Note:
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|
|
